Literature DB >> 19141292

Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line.

Yuji Mikami1, Akinori Hisatsune, Tomomi Tashiro, Yoichiro Isohama, Hiroshi Katsuki.   

Abstract

Expression of a transmembrane mucin MUC1 is emphasized in most cases of carcinoma. High expression of MUC1 is closely associated with cancer progression and metastasis, leading to poor prognosis. However, little is known about how MUC1 is overexpressed in malignant tumor. In this study, we demonstrated that: (1) Hypoxia, a typical feature of malignant tumor, enhanced the expression of MUC1 mRNA and protein in a human lung adenocarcinoma cell line; (2) the hypoxia-induced increase in MUC1 mRNA was mediated by the transcriptional activity of MUC1 promoter, but not mRNA stability. Moreover; (3) CoCl(2), an inducer of Hypoxia Inducible Factor (HIF)-1alpha, increased the expression of MUC1 mRNA; and (4) HIF-1alpha-targeted siRNA but not its control siRNA decreased hypoxia-induced MUC1 mRNA. These data suggest that hypoxia enhances the expression of MUC1 through the transcriptional regulation by HIF-1alpha in a human lung epithelial cell line.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19141292     DOI: 10.1016/j.bbrc.2009.01.002

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Adrenomedullin 2 (ADM2) Regulates Mucin 1 at the Maternal-Fetal Interface in Human Pregnancy.

Authors:  Madhu Chauhan; Meena Balakrishnan; Rexanna Chan; Chandrasekhar Yallampalli
Journal:  Biol Reprod       Date:  2015-10-28       Impact factor: 4.285

2.  HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells.

Authors:  Jingqi Yan; Ziyan Zhang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2011-05-27       Impact factor: 9.261

Review 3.  MUC1: a novel metabolic master regulator.

Authors:  Kamiya Mehla; Pankaj K Singh
Journal:  Biochim Biophys Acta       Date:  2014-01-11

4.  MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1.

Authors:  Mohit Sachdeva; Yin-Yuan Mo
Journal:  Cancer Res       Date:  2009-12-08       Impact factor: 12.701

5.  Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis.

Authors:  Nadine Rohwer; Sandra Jumpertz; Merve Erdem; Antje Egners; Klaudia T Warzecha; Athanassios Fragoulis; Anja A Kühl; Rafael Kramann; Sabine Neuss; Ines Rudolph; Tobias Endermann; Christin Zasada; Ivayla Apostolova; Marco Gerling; Stefan Kempa; Russell Hughes; Claire E Lewis; Winfried Brenner; Maciej B Malinowski; Martin Stockmann; Lutz Schomburg; William Faller; Owen J Sansom; Frank Tacke; Markus Morkel; Thorsten Cramer
Journal:  Oncogene       Date:  2019-05-01       Impact factor: 9.867

6.  MUC1 expression in pulmonary metastatic tumors: a comparison of primary lung cancer.

Authors:  Kyoichi Kaira; Takehiro Okumura; Kazuo Nakagawa; Yasuhisa Ohde; Toshiaki Takahashi; Haruyasu Murakami; Tateaki Naito; Masahiro Endo; Haruhiko Kondo; Takashi Nakajima; Nobuyuki Yamamoto
Journal:  Pathol Oncol Res       Date:  2011-10-02       Impact factor: 3.201

Review 7.  Targeting hypoxic response for cancer therapy.

Authors:  Elisa Paolicchi; Federica Gemignani; Marija Krstic-Demonacos; Shoukat Dedhar; Luciano Mutti; Stefano Landi
Journal:  Oncotarget       Date:  2016-03-22

Review 8.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

Review 9.  Hypoxia and Integrin-Mediated Epithelial Restitution during Mucosal Inflammation.

Authors:  Bridie J Goggins; Ciaran Chaney; Graham L Radford-Smith; Jay C Horvat; Simon Keely
Journal:  Front Immunol       Date:  2013-09-11       Impact factor: 7.561

Review 10.  Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer.

Authors:  Yue Ning; Hongmei Zheng; Yuting Zhan; Sile Liu; Yang Yang; Hongjing Zang; Jiadi Luo; Qiuyuan Wen; Songqing Fan
Journal:  J Exp Clin Cancer Res       Date:  2020-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.